BDR Pharma buys majority stake in Acme’s oral solids formulations business
LiveMint

BDR Pharma is acquiring a majority stake in Acme's oral solids formulations business in a deal valuing the enterprise at about $250 million.
BDR Pharma has agreed to purchase a majority stake in the oral solids formulations business of Acme. As part of the transaction, existing investors such as private equity firm PAG are selling their stakes. The overall deal is expected to value the targeted business at approximately $250 million.
Why it matters: The transaction highlights ongoing consolidation and private equity exits in the pharmaceutical sector with a $250 million valuation.






